Skip to main content
Name a drug, target, or condition and Anara searches ClinicalTrials.gov, PubMed, and bioRxiv simultaneously, then summarizes what is in development, what has reported, and what is worth paying attention to. Covers trial phases, enrollment status, sponsors, and published findings. No files to upload.

​
1. Describe the task

A drug program moves fast. A trial you followed six months ago has a new cohort, a competitor announced Phase 2 results last week, and the ClinicalTrials.gov registry has been updated twice since you last checked. Assembling the current picture manually means switching between databases, chasing NCT numbers, and cross-referencing registry entries against published abstracts. Anara searches ClinicalTrials.gov, PubMed, and bioRxiv simultaneously from a single prompt. It returns what is currently registered, what phase each trial is in, which sponsors are active, and where published data is available. For targets or conditions with substantial trial activity, it identifies what the evidence landscape looks like across phases: which efficacy signals are established, which are still recruiting, and which are ongoing without published results. The output is a structured picture of the field as it currently stands, grounded in live registry data and indexed literature, not in a review article published eighteen months ago. Here a clinical pharmacologist at a specialty pharmaceutical company is assessing the competitive landscape for a new indication of an existing drug before a portfolio decision meeting. 
Pull the latest clinical trial data on GLP-1 receptor agonists for non-alcoholic steatohepatitis from PubMed, bioRxiv, and ClinicalTrials.gov. I want to know: which trials are currently recruiting or active, what phases they are in, who the sponsors are, what the primary endpoints are, and where published efficacy or safety data already exists. Summarize what is worth paying attention to and flag any trials that have reported preliminary results in the last 12 months.

​
2. Give Anara context

Required context
  • Nothing to upload. The prompt carries it. Anara searches the live databases directly.
Optional context
  • A date range if you want only recent activity. “Trials registered or updated since January 2024” focuses the search.
  • Specific phases if you care only about late-stage evidence. “Phase 2 and Phase 3 only” removes early-stage exploratory studies.
  • A comparator or mechanism of action if you are tracking a specific class rather than a single target.

​
3. What Anara creates

A structured summary organized by the current state of the evidence: trials with published results, trials in active stages, trials in early or planning phases. Each entry includes the NCT identifier, sponsor, current status, phase, primary endpoint, and a link to the ClinicalTrials.gov record. Where PubMed or bioRxiv has a published paper tied to the trial, Anara links both. The output is what you read before a portfolio decision, a competitive review, or a due diligence call to understand what the field has tested and what it has not.

​
4. Follow-up prompts

​
Go deeper on one trial

When the summary surfaces a trial that needs a closer read. 
Go deeper on the semaglutide NASH trial that appeared in the results. What were the primary and secondary endpoints as registered? Has anything been published on interim data? Who is running the trial and what is the estimated completion date?

​
Find the published papers tied to a set of trials

When you want to move from registry data to actual results. 
For the three Phase 3 trials you identified, find any published papers reporting results in PubMed or bioRxiv. Return the abstracts and flag whether the paper is a primary results paper or a secondary analysis.

​
Compare trial designs across sponsors

When you want to understand how different programs are approaching the same indication. 
Compare the primary endpoint designs across the four active NASH trials you identified. How are sponsors defining the primary outcome: liver biopsy-confirmed resolution, non-invasive biomarker improvement, or something else? Where do the approaches diverge?

​
5. Tricks, tips, and troubleshooting

​
How you word your prompt shapes what you get

Name all three sources explicitly: ClinicalTrials.gov, PubMed, and bioRxiv. Without naming them, Anara may default to the general academic search index, which covers PubMed but may not prioritize registry data. For narrow targets with few trials, the three-source search is fast. For large indications with hundreds of trials (oncology, cardiovascular, diabetes), add filters: phase, status, date range. “Active or recruiting trials” removes completed studies you probably already know about. “Sponsored by [company]” focuses the search on a specific competitor program.

​
Check the output against your own understanding

ClinicalTrials.gov data is as current as the sponsor’s last update to the registry. Sponsors are required to update, but some trial records lag weeks or months behind actual study progress. If a trial looks inactive but you have seen recent conference data from it, check the primary endpoint date on the registry directly. For PubMed coverage: Anara retrieves abstracts and metadata for most indexed papers, but full text is only available when the paper is open access. Anara will tell you when a paper is available for import versus abstract-only.

​
What to do with the output next

Import the published papers that look most relevant to your analysis. Once they are in your library, you can interrogate them in detail: extract efficacy data, compare endpoint definitions, or check whether the safety signals in one trial appear in another. For ongoing monitoring, save the initial summary as a note and refresh it periodically: paste the note into a new chat, ask Anara to check for updates since the note’s date, and update the note with new developments. This gives you a living competitive intelligence document rather than a one-off snapshot.